Question 1

Has Bibi Das received payments from drug or device companies?

Accepted Answer

Yes. Drug and device makers reported $1,370,438 in general payments to Bibi Das across 2,419 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Question 2

Does a payment mean Bibi Das did something wrong?

Accepted Answer

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Question 3

Where does this information about Bibi Das come from?

Accepted Answer

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Company	Payments	Total
Axsome Therapeutics, Inc.	573	$426,872
AbbVie(2 entities)	762	$296,899
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)	345	$272,845
Neurocrine Biosciences, Inc.	123	$92,008
Sunovion Pharmaceuticals Inc.	189	$89,649
Otsuka America Pharmaceutical, Inc.	160	$79,563
Teva Pharmaceuticals USA, Inc.	111	$54,256
Vanda Pharmaceuticals Inc.	40	$32,523
E.r. Squibb & Sons, L.L.C.	39	$23,289
Takeda Pharmaceuticals U.S.A., Inc.	34	$1,408
Lundbeck LLC	31	$710
Otsuka Pharmaceutical Development & Commercialization, Inc.	2	$142
Corium, LLC	1	$77
Alkermes, Inc.	3	$72
Eisai Inc.	2	$55
Shire North American Group Inc	3	$45
Indivior Inc.	1	$27

Bibi Das

Payments from drug & device makers

Who reported the general payments

How this compares

Other psychiatry in Stanford